H. Brisse

Institut Curie, Lutetia Parisorum, Île-de-France, France

Are you H. Brisse?

Claim your profile

Publications (82)90.37 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Le rétinoblastome est la tumeur maligne intraoculaire la plus fréquente de l’enfant. Sa prévalence est de 1/15 000 naissances. Soixante pour cent des cas sont unilatéraux avec un âge médian au diagnostic de 2 ans. Dans 40 % des cas, le rétinoblastome est bilatéral, avec un âge médian de survenue de 1 an. Toutes les formes bilatérales et unilatérales multifocales sont héréditaires. Le rétinoblastome héréditaire est un syndrome de prédisposition génétique au cancer : un sujet porteur d’une mutation constitutionnelle du gène RB1 présente un risque supérieur à 90 % de développer un rétinoblastome et est par ailleurs exposé au risque de tumeur secondaire. Les deux signes cliniques les plus fréquents sont la leucocorie et le strabisme. L’examen du fond d’œil permet le diagnostic, l’échographie, l’imagerie par résonance magnétique (IRM) pouvant également y contribuer. La prise en charge des patients doit avoir lieu en milieu spécialisé et prendre en compte divers facteurs : le potentiel visuel, la nature possiblement héréditaire de l’affection et le risque vital. Dans les pays industrialisés, le pronostic vital est bon (survie globale > 95 %) ; toutefois, les patients atteints de forme héréditaire sont à risque de développer des cancers secondaires et d’avoir de ce fait une espérance de vie diminuée. Dans les pays à faible revenu, du fait d’un diagnostic souvent tardif et parfois de moyens thérapeutiques non disponibles, le rétinoblastome reste fréquemment mortel. Une énucléation est souvent nécessaire dans la forme unilatérale, un traitement adjuvant étant indiqué en fonction des facteurs de risques histologiques. Un traitement conservateur pour au moins un œil est possible dans la plupart des formes bilatérales : thermochimiothérapie, cryothérapie, laser, curiethérapie par disque d’iode, chimiothérapie intra-arterielle, intravitréenne. Les indications de radiothérapie externe sont aujourd’hui très limitées aux grosses tumeurs avec essaimage vitréen ou aux rechutes, en raison des risques de sarcomes secondaires. Un suivi à long terme et une information précoce des patients et de leur famille concernant les risques de transmission et de tumeurs secondaires sont nécessaires.
    No preview · Article · Dec 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: To describe the results of retinoblastoma treatment from 1995-2009 in a single institution. Retrospective review of the charts of patients treated for retinoblastoma. Clinical characteristics at diagnosis, treatments and outcomes in terms of survival and ocular preservation are described. During the study period 826 children were referred for retinoblastoma and 730 were managed in our institution. Four hundred and eleven children presented with unilateral retinoblastoma and 319 with bilateral retinoblastoma. Median follow-up is of 93 months. Global survival is 98.5% of children, 10 children presented with second tumors, 11 children died (6 of tumor-related causes). Of the 411 children with unilateral retinoblastoma enucleation was needed at diagnosis for 324 (78.8%). Conservative treatments were attempted for 87 patients (21.2%) and ocular preservation obtained for 65 patients (74% of eyes). Three hundred and nineteen patients presented with bilateral retinoblastoma. Three hundred and ten could be treated conservatively for at least one eye. Initial intravenous chemotherapy was necessary for 75% of them. Ocular preservation without external beam radiation was possible for 221 patients (70%). The use of EBR decreased significantly after 2004 (9.1% of eyes vs 25.1%: P<0.001). Management and treatment of retinoblastoma are complex, adapted to the extent of the disease. Survival is good. Enucleation is still required for extensive ocular disease, especially for unilateral patients. Intravenous chemotherapy allows good tumor control and eye preservation and decrease the need of EBR. Retinoblastoma treatment with intravenous chemotherapy and ocular adjuvant therapies is very effective on the local tumor control and eye preservation. Copyright © 2015 Elsevier Masson SAS. All rights reserved.
    No preview · Article · May 2015 · Journal francais d'ophtalmologie
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Recent epidemiological results suggested an increase of cancer risk after receiving computed tomography (CT) scans in childhood or adolescence. Their interpretation is questioned due to the lack of information about the reasons for examination. Our objective was to estimate the cancer risk related to childhood CT scans, and examine how cancer-predisposing factors (PFs) affect assessment of the radiation-related risk. Methods: The cohort included 67,274 children who had a first scan before the age of 10 years from 2000 to 2010 in 23 French departments. Cumulative X-rays doses were estimated from radiology protocols. Cancer incidence was retrieved through the national registry of childhood cancers; PF from discharge diagnoses. Results: During a mean follow-up of 4 years, 27 cases of tumours of the central nervous system, 25 of leukaemia and 21 of lymphoma were diagnosed; 32% of them among children with PF. Specific patterns of CT exposures were observed according to PFs. Adjustment for PF reduced the excess risk estimates related to cumulative doses from CT scans. No significant excess risk was observed in relation to CT exposures. Conclusions: This study suggests that the indication for examinations, whether suspected cancer or PF management, should be considered to avoid overestimation of the cancer risks associated with CT scans.
    Full-text · Article · Oct 2014 · British Journal of Cancer
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Radiation treatment of GCT brain, in particular germinomas which are highly radio-sensitive,over the years has evolved from the cranio-spinal irradiation(CSI) to more conformal treatment like whole ventricle radiation followed by tumor bed boost (WV + TB), without compromising the results. We report our experience of treatment outcome of patients treated consecutively over a period of more than ten years with both the methods. METHOD: Twelve consecutive patients registered and treated in radiotherapy department between 2000 and 2013 after surgery (biopsy/decompression) and chemotherapy, were analysed in December 2013. Total Number (Histo-pathology) 12 (Germinoma- 9, Non-Germinoma-2, No histology-1); Median age (Years) 13 (Range 5-24 years); Gender-M/F (%) 10:2(83:17); Co-morbidities None; Pre-Surgery KPS >90 (92%); Surgery (n) Biopsy/Decompression± VP shunt (11), No Surgery (1); Sub-site Pineal- 7(58%), Supra-sellar-5(42%). TREATMENT: Ten patients received 3D-CRT, while two received IMRT. Three received CSI while nine received WV + TB. CSI dose ranged from 23.4 Gy - 36 Gy in 13-20 fractions. For WV the intended dose was 36Gy/20 fractions followed by 9Gy/5 fractions to TB. Pre-radiation all received combination chemotherapy, cisplatin or carboplatin ± etoposide ± irinotecan. RESULTS: All the patients tolerated and completed treatment with no serious adverse effects. Follow-up was done with serial tumor markers, hormonal, visual, auditory assessment and MRI. Two patients,both non-germinomas treated with CSI progressed and died with-in one year of treatment. Ten patients (9-germinomas, 1-no histology) till date are doing fine,without any loco-regional or distant failures. Ten year overall survival is around 80%.Two patients have developed hormonal imbalance and are on treatment,while one of them developed progressive bilateral optic atrophy which was present prior to radiotherapy. CONCLUSION:Our results are comparable with the reported literature.The overall survival in Germinomas is 100%,Treatment related effects are minimal as a result of reduced dose and limited treatment volume,contributing possibly to better outcome along with various other reasons.
    Full-text · Article · Jun 2014 · Neuro-Oncology

  • No preview · Article · Oct 2013 · Cancer/Radiothérapie

  • No preview · Article · Sep 2013 · Pediatric Blood & Cancer
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: The diagnosis of atypical teratoid/rhabdoid tumor (AT/RT) may pose difficulties. We therefore aim to share our experiences as reference pathologists within the European Rhabdoid Tumor Registry (EURHAB) and the International Choroid Plexus Tumor Registry CPT-SIOP. METHODS: Evaluation of clinical, histological and molecular genetic features of AT/RT diagnosed at the Institute of Neuropathology, University Hospital Münster. RESULTS: In the vast majority of brain tumors (46/47) seen in the context of the European Rhabdoid Tumor Registry (EURHAB), the diagnosis of AT/RT could be confirmed. The median age of the patients was 1 year (interquartile range 1-3), 59% of tumors were located supratentorially. Loss of nuclear SMARCB1/INI1 staining was encountered in 44 tumors (96%), but SMARCB1/INI1 staining was retained in two cases. In one of those, loss of protein expression of another SWI/SNF chromatin-remodeling complex member, the ATPase subunit SMARCA4/BRG1 due to a homozygous mutation could be demonstrated. A number of 14 CPT-SIOP cases, which had been suspected to represent choroid plexus carcinoma, also turned out to be AT/RT. The median age of the patients was 1 year (interquartile range 1-3), only 29% of tumors were of supratentorial location. Twelve tumors showed loss of nuclear SMARCB1/INI1 staining (86%), but SMARCB1/INI1 staining was retained in two cases, one showing loss of SMARCA4/BRG1 expression due to a homozygous mutation. CONCLUSIONS: In the majority of cases seen within EURHAB, the diagnosis of AT/RT was confirmed. The high number of AT/RT encountered within CPT-SIOP highlights the importance of considering AT/RT as a differential diagnosis in cases suspected to be choroid plexus carcinoma. Importantly, retained SMARCB1/INI1 staining does not rule out the possibility of AT/RT and genetic alterations of other members of the SWI/SNF complex, namely SMARCA4/BRG1, need to be considered. SUPPORT: MH and WP are supported by IZKF Münster (Ha3/016/11) and Deutsche Krebshilfe (DK 108263).
    Full-text · Article · Jun 2012 · Neuro-Oncology

  • No preview · Article · Jun 2011 · Revue d Épidémiologie et de Santé Publique
  • N. Pierrat · S. Lasalle · H. Brisse

    No preview · Article · Jun 2011 · Physica Medica
  • J-F Chateil · B Aubert · H Brisse
    [Show abstract] [Hide abstract]
    ABSTRACT: Radiologists should be able to appreciate the radiation dose delivered to patients for routine diagnostic procedures. The radiology report should include data necessary to calculate the patient dose in Gray. Using the effective dose, it is possible to compare with other source of radiation exposure. Simple formulas, taking into account different anatomical regions, derived from dose-area product (conventional radiography) or dose-length product (CT) are provided to calculate the effective dose in Sievert. For conventional (non-interventional) radiography, the effective dose for a given exam is inferior or equal to the yearly background radiation. For CT, the effective dose corresponds to 1 to 10 years of yearly background radiation.
    No preview · Article · Nov 2010 · Journal de Radiologie
  • Source
    J.-F. Chateil · B. Aubert · H. Brisse
    [Show abstract] [Hide abstract]
    ABSTRACT: Radiologists should be able to appreciate the radiation dose delivered to patients for routine diagnostic procedures. The radiology report should include data necessary to calculate the patient dose in Gray. Using the effective dose, it is possible to compare with other source of radiation exposure. Simple formulas, taking into account different anatomical regions, derived from dose-area product (conventional radiography) or dose-length product (CT) are provided to calculate the effective dose in Sievert. For conventional (non-interventional) radiography, the effective dose for a given exam is inferior or equal to the yearly background radiation. For CT, the effective dose corresponds to 1 to 10 years of yearly background radiation.
    Full-text · Article · Nov 2010 · Journal de Radiologie
  • [Show abstract] [Hide abstract]
    ABSTRACT: Primary malignant nasopharyngeal tumors are relatively rare in children. The most frequent childhood neoplasms in this region are rhabdomyosarcoma (RMS), Undifferentiated Carcinoma of Nasopharyngeal Type (UCNT) and Non-Hodgkin's Lymphoma (NHL). Children with these tumors usually present with nasal obstruction, headache, nasal swelling or cervical node involvement. The nasopharyngeal mass may be discovered during an ear, nose and throat examination and is confirmed by medical imaging. The diagnosis may be suspected on fine needle aspiration and is confirmed by biopsy of the nasopharyngeal mass or cervical lymph node. The treatments and prognoses differ for these 3 types of tumors. The objective of this paper is to review the diagnostic and therapeutic approach to childhood malignant nasopharyngeal tumors such as RMS, NHL and UCNT. The authors also review the known prognostic factors of these diseases in order to discuss treatment adaptation, especially in young children.
    No preview · Article · Jan 2010
  • [Show abstract] [Hide abstract]
    ABSTRACT: Medulloblastoma patients treated at the Institute Curie between 1980 and 2000 were reviewed. Only patients whose primary treatment included craniospinal radiation were considered. Surviving patients were identified and evaluated by means of self-report questionnaires using the Health Utility Index (HUI). Psychosocial functioning, employment, and other health-related indicators were recorded. Seventy-three patients were treated during the study period. At a median follow-up from diagnosis of 14.4 years, 49 patients were alive and 45 surviving patients could be contacted. Late sequelae were frequent, particularly neurological deficits (71%) and endocrine complications (52%). Impairments of psychosocial functioning, including employment, driving capacity, independent living, and marital status, were identified in most patients. Most long-term medulloblastoma survivors suffer persistent deficits in several domains, with a significant impact on their psychosocial functioning. These findings reinforce the importance of early intervention programs for all survivors in order to reduce the psychosocial impacts of their disease.
    No preview · Article · Nov 2009 · Journal of Neuro-Oncology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction Diagnosis of choroidal hematoma, either spontaneous or associated with age-related macular degeneration, is clinical. In some cases of expansive or posterior lesion, hematoma may be misdiagnosed as a tumor. MRI and color Doppler imaging (CDI) are important in ruling out uveal melanoma in these cases. Patients and methods We reviewed the clinical, MRI, and ultrasonographic characteristics of 95 patients sent to the Curie Institute for suspected uveal melanoma between 1998 and 2006, whose final diagnosis was a choroidal hematoma. Imaging differences with melanomas are discussed. Results A total of 95 patients with a diagnosis of hematoma were seen; the age varied from 54 to 92 years with a median age of 77 years; there was a history of macular degeneration in 27 cases and 11 patients were taking an anticoagulant. Intravitreous hemorrhage was noted in 18 cases and the lesion was located in the posterior pole in 28 cases. The thickness of the lesions measured by B scan ultrasonography varied between 1 and 7.8 mm, with a mean thickness of 2.86 mm. MRI was performed in 27 cases and CDI in ten cases. On CDI, hematomas appeared as linear or regular bulging lesions with no intralesional blood flow. On MRI, hematomas appeared as a high-intensity signal on T1-weighted images, heterogeneous on T2-weigted images in relation to the progression of the clot, but no contrast enhancement was noted inside the lesion. Follow-up examinations showed the progressive involvement of the clot and delayed decreasing size of the lesion. Conclusion The diagnosis of choroidal hematoma is usually made by fundus examination. In some posterior locations with pseudo-tumoral appearance, CDI and MRI are useful to rule out a uveal tumor.
    No preview · Article · Nov 2009 · Journal francais d'ophtalmologie
  • [Show abstract] [Hide abstract]
    ABSTRACT: Diagnosis of choroidal hematoma, either spontaneous or associated with age-related macular degeneration, is clinical. In some cases of expansive or posterior lesion, hematoma may be misdiagnosed as a tumor. MRI and color Doppler imaging (CDI) are important in ruling out uveal melanoma in these cases. We reviewed the clinical, MRI, and ultrasonographic characteristics of 95 patients sent to the Curie Institute for suspected uveal melanoma between 1998 and 2006, whose final diagnosis was a choroidal hematoma. Imaging differences with melanomas are discussed. A total of 95 patients with a diagnosis of hematoma were seen; the age varied from 54 to 92 years with a median age of 77 years; there was a history of macular degeneration in 27 cases and 11 patients were taking an anticoagulant. Intravitreous hemorrhage was noted in 18 cases and the lesion was located in the posterior pole in 28 cases. The thickness of the lesions measured by B scan ultrasonography varied between 1 and 7.8mm, with a mean thickness of 2.86mm. MRI was performed in 27 cases and CDI in ten cases. On CDI, hematomas appeared as linear or regular bulging lesions with no intralesional blood flow. On MRI, hematomas appeared as a high-intensity signal on T1-weighted images, heterogeneous on T2-weigted images in relation to the progression of the clot, but no contrast enhancement was noted inside the lesion. Follow-up examinations showed the progressive involvement of the clot and delayed decreasing size of the lesion. The diagnosis of choroidal hematoma is usually made by fundus examination. In some posterior locations with pseudo-tumoral appearance, CDI and MRI are useful to rule out a uveal tumor.
    No preview · Article · Oct 2009 · Journal francais d'ophtalmologie
  • S. Sarnacki · H. Brisse · G. Schleiermacher · F. Doz

    No preview · Article · Jan 2009 · Medecine Therapeutique Pediatrie
  • H. Brisse · B. Bourlière-Najean

    No preview · Article · Oct 2008 · Journal de Radiologie
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objectifs L’utilisation du scanner en pédiatrie pose la question du risque de cancer radio-induit à long terme. En collaboration avec la SFIPP, la faisabilité de la mise en place d’une cohorte d’enfants exposés a été testée. Matériels et méthodes Dans 13 services de radiologie pédiatrique, des données démographiques et d’exposition (région anatomique examinée, protocole dosimétrique du service) ont été recueillies pour les enfants soumis à un scanner avant l’âge de 5 ans entre 2000 et 2006. Résultats La cohorte comporte 30 000 enfants avec un âge au premier scanner de moins d’ 1 an pour 42 % d’entre eux, de 1 à 2 ans pour 19 %, puis 13 % pour chaque classe d’âge d’un an, jusqu’à 5 ans. Le nombre moyen d’examens par enfant est de 1,5 (1 à 33) et ceux-ci concernent pour 66 % le crâne, 22 % le thorax, 10 % l’abdomen et le pelvis, et enfin pour 2 % d’autres localisations. Conclusion Cette étude montre qu’il est possible de mettre en place une cohorte d’enfants soumis à un scanner en France. L’évaluation du risque de cancer à long terme sera basée sur l’incidence de cancer jusqu’à 15 ans via les registres pédiatriques de cancer et sur la mortalité pour le suivi ultérieur.
    Full-text · Article · Oct 2008 · Journal de Radiologie
  • Source
    H. Brisse · B. Aubert
    [Show abstract] [Hide abstract]
    ABSTRACT: Objectifs Réévaluer les niveaux actuels d’exposition en TDM pédiatrique afin de contribuer à l’établissement des niveaux de référence diagnostiques. Matériels et méthodes Fin 2007, les membres de la SFIPP ont reçu une fiche de recueil incluant la dose absorbée (CTDIvol16/tête et cou, CTDIvol32/tronc et membres) pour trois âges types (1,5 et 10 ans) et des indications types sur huit régions anatomiques (crâne, massif facial, sinus, rochers, thorax, poumon « basse dose », abdomen-pelvis et os). Résultats L’analyse a porté sur 20 sites hospitaliers. Pour les âges de 1,5 et 10 ans respectivement, les 75èmes centiles des distributions de doses étaient de : 34,41 et 50 mGy pour le crâne ; 24,22 et 24 mGy pour le massif facial ; Il, Il et 11 mGy pour les sinus ; 48,71 et 85 mGy pour les rochers ; 3,3, 5 et 6 mGy pour le thorax ; 2,3 et 4 mGy pour le poumon « basse dose » ; 4,5 et 7 mGy pour l’abdomen-pelvis ; et 7,11 et 13 mGy pour l’os. Conclusion Comparativement au guide des procédures (2005), les valeurs sont légèrement supérieures pour le crâne, les sinus et les rochers. Les écarts dosimétriques inter-centres restent élevés.
    Full-text · Article · Oct 2008 · Journal de Radiologie
  • H. Brisse
    [Show abstract] [Hide abstract]
    ABSTRACT: Donner aux participants les moyens de maîtriser les différents indicateurs dosimétriques utilisés en scanographie, quel que soit le type de scanner, pour quantifier la dose délivrée au cours d’un examen : l’Indice de Dose de Scanographie Pondéré (CTDIw), l’Indice de Dose de Scanographie au Volume (CTDIvol), le produit « Dose. Longueur » (PDL) et la dose efficace.La définition et la signification exacte de chaque grandeur seront précisées, ainsi que les équations simplifiées qui les relient entre elles.L’influence des paramètres d’exposition (kV, mAs, pitch, épaisseur de coupe, nombre de coupes par rotation, etc.) sur la dose délivrée aux patients sera analysée.Connaître les informations dosimétriques concernées par les NRD.Points clésLa scanographie est la technique d’imagerie radiologique la plus irradiante pour le patient.Le produit dose. longueur est un indicateur du risque.Ne pas oublier de comparer ses pratiques avec les procédures décrites dans le Guide des procédures.Ne pas oublier de relever les données dosimétriques relatives aux NRD.
    No preview · Article · Oct 2008 · Journal de Radiologie

Publication Stats

761 Citations
90.37 Total Impact Points

Institutions

  • 2003-2015
    • Institut Curie
      • Service de Radiothérapie
      Lutetia Parisorum, Île-de-France, France
  • 2014
    • Pierre and Marie Curie University - Paris 6
      Lutetia Parisorum, Île-de-France, France
  • 2010
    • Centre Hospitalier Universitaire de Bordeaux
      Burdeos, Aquitaine, France
  • 2001-2006
    • Institut de Cancérologie Gustave Roussy
      • Department of Radiotherapy
      Île-de-France, France
  • 1996-2001
    • Hôpital Universitaire Robert Debré
      • Service d’Imagerie Pédiatrique
      Lutetia Parisorum, Île-de-France, France